Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Insmed Incorporated has entered into an exclusive option agreement with University of California, San Francisco School of Medicine for the patented use of a series of IGF-1 receptor antagonists to treat prostate cancer.
Subscribe to our email newsletter
This application of IGF-1 receptor antagonists complements Insmed and UCSF’s ongoing clinical studies with INSM-18, a small molecule IGF-1 tyrosine kinase inhibitor in a phase I clinical study in patients with relapsed prostate cancer.
Researchers at University of California, San Francisco (UCSF), a National Cancer Institute designated Comprehensive Cancer Center, will lead the investigative efforts with IGF-1 receptor antagonists to identify the compound with an ideal risk/benefit ratio to enter clinical trials.
“We are very excited to expand the company pipeline with this patented methodology,” commented Insmed’s CEO Dr Geoffrey Allan. “This agreement with UCSF further broadens our pipeline of promising drug candidates in the prostate cancer field, and reinforces Insmed as a leader in IGF biology and growth factor signaling.”